Transporters in Anti-Parasitic Drug Development and Resistance

Trypanosomatid Diseases: Molecular Routes to Drug Discovery

Volumn , Issue , 2013, Pages 335-349

  Delespaux, Vincent ^a   De Koning, Harry P ^b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Anti parasitic; Drug development; Drug resistance; Mutation; Screening; Transporter

Indexed keywords

EID: 84884250945     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527670383.ch18     Document Type: Chapter

References (87)

1. Delespaux, V. and De Koning, H.P. (2007) Drugs and drug resistance in African trypanosomiasis. Drug Resist. Updat., 10, 30-50.
2. Shahi, S.K., Krauth-Siegel, R.L., and Clayton, C. (2002) Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei. Mol. Microbiol., 43, 1129-1138.
3. Lipinski, C.A., Lombardo, F., and Dominy, B.W. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 46, 3-26.
4. Sarkadi, B. and Szakács, G. (2010) Understanding transport through pharmacological barriers -are we there yet? Nat. Rev. Drug Discov., 9, 897-898.
5. Dobson, P.D. and Kell, D.B. (2008) Carriermediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug. Discov., 7, 205-220.
6. Balimane, P.V., Han, Y.H., and Chong, S. (2006) Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J., 8, E1-E13.
7. Opekarová, M. and Tanner, W. (2003) Specific lipid requirements of membrane proteins -a putative bottleneck in heterologous expression. Biochim. Biophys. Acta, 1610, 11-22.
8. Barrett, M.P. and Gilbert, I.H. (2002) Perspectives for new drugs against trypanosomiasis and leishmaniasis. Curr. Top. Med. Chem., 2, 471-482.
9. Enanga, B., Burchmore, R.J.S., Stewart, M. L., and Barrett, M.P. (2002) Sleeping sickness and the brain. Cell. Mol. Life Sci., 59, 845-858.
10. Barrett, M.P., Burchmore, R.J., Stich, A., Lazzari, J.O., Frasch, A.C., Cazzulo, J.J., and Krishna, S. (2003) The trypanosomiases. Lancet, 362, 1469-1480.
11. Zlokovic, B.V. (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron, 57, 178-201.
12. Lee, G., Dallas, S., Hong, M., and Bendayan, R. (2001) Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev., 53, 569-596.
13. Pardridge, W.M. (2007) Blood-brain barrier delivery. Drug Discov. Today, 12, 54-61.
14. De Boer, A.G., Van der Sandt, I.C.J., and Gaillard, P.J. (2003) The role of transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol., 43, 629-656.
15. Sanderson, L., Dogruel, M., Rodgers, J., De Koning, H.P., and Thomas, S.A. (2009) Pentamidine movement across the murine blood-brain and blood-CSF barriers; effect of trypanosome infection, combination therapy, P-glycoprotein and MRP. J. Pharmacol. Exp. Ther., 329, 967-977.
16. Fitch, C.D. (1969) Chloroquine resistance in malaria: a deficiency of chloroquine binding. Proc. Natl. Acad. Sci. USA, 64, 1181-1187.
17. Hawley, S.R., Bray, P.G., O'Neill, P.M., Park, B.K., and Ward, S.A. (1996) The role of drug accumulation in 4-aminoquinoline antimalarial potency. The influence of structural substitution and physicochemical properties. Biochem. Pharmacol., 52, 723-733.
18. Polet, H. and Barr, C.F. (1969) Uptake of chloroquine-3H by Plasmodium knowlesi in vitro. J. Pharmacol. Exp. Ther., 168, 187-192.
19. Bray, P.G., Janneh, O., Raynes, K.J., Mungthin, M., Ginsburg, H., and Ward, S. A. (1999) Cellular uptake of chloroquine is dependent on binding to ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. J. Cell Biol., 145, 363-376.
20. Homewood, C.A., Warhurst, D.C., Peters, W., and Baggaley, V.C. (1972) Lysosomes, pH and the anti-malarial action of chloroquine. Nature, 235, 50-52.
21. Fitch, C.D. (2004) Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci., 74, 1957-1972.
22. Sidhu, A.B., Verdier-Pinard, D., and Fidock, D.A. (2002) Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science, 298, 210-213.
23. Lakshmanan, V., Bray, P.G., Verdier-Pinard, D., Johnson, D.J., Horrocks, P., Muhle, R.A., Alakpa, G.E. et al. (2005) A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J., 24, 2294-2305.
24. Bray, P.G., Mungthin, M., Hastings, I.M., Biagini, G.A., Saidu, D.K., Lakshmanan, V., Johnson, D.J. et al. (2006) PfCRTand the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Mol. Microbiol., 62, 238-251.
25. Krogstad, D.J., Gluzman, I.Y., Kyle, D.E., Oduola, A.M., Martin, S.K., Milhous, W.K., and Schlesinger, P.H. (1987) Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science, 238, 1283-1285.
26. Duraisingh, M.T. and Cowman, A.F. (2005) Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop., 94, 181-190.
27. Ross, M.F., Prime, T.A., Abakumova, I., James, A.M., Porteous, C.M., Smith, R.A., and Murphy, M.P. (2008) Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem. J., 411, 633-645.
28. Ross, M.F., Kelso, G.F., Blaikie, F.H., James, A.M., Cochemé, H.M., Filipovska, A., Da Ros, T. et al. (2005) Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc.), 70, 222-230.
29. Smith, R.A., Adlam, V.J., Blaikie, F.H., Manas, A.R., Porteous, C.M., James, A.M., Ross, M.F. et al. (2008) Mitochondriatargeted antioxidants in the treatment of disease. Ann. NY Acad. Sci., 1147, 105-111.
30. Luque-Ortega, J.R., Reuther, P., Rivas, L., and Dardonville, C. (2010) New benzophenone-derived bisphosphonium salts as leishmanicidal leads targeting mitochondria through inhibition of respiratory complex II. J. Med. Chem., 53, 1788-1798.
31. Taladriz, A., Healy, A., Flores Pérez, E.J., Herrero García, V., Ríos Martínez, C., Alkhaldi, A.A., Eze, A.A. et al. (2012) Synthesis and structure-activity analysis of new phosphonium salts with potent activity against African trypanosomes. J. Med. Chem., 55, 2606-2622.
32. Paine, M.,Wang, M., Boykin, D., Wilson, W.D., De Koning, H.P., Olson, C., Polig, G. et al. (2010) Diamidines for human African trypanosomiasis. Curr. Opin. Investig. Drugs, 11, 876-883.
33. Bray, P.G., Barrett, M.P.,Ward, S.A., and De Koning, H.P. (2003) Pentamidine uptake and resistance in pathogenic protozoa. Trends Parasitol., 19, 232-239.
34. Damper, D. and Patton, C.L. (1976) Pentamidine transport and sensitivity in brucei-group trypanosomes. J. Protozool., 23, 349-356.
35. Damper, D. and Patton, C.L. (1976) Pentamidine transport in Trypanosoma brucei -kinetics and specificity. Biochem. Pharmacol., 25, 271-276.
36. De Koning, H.P. (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters. Implications for crossresistance with arsenicals. Mol. Pharmacol., 59, 586-592.
37. Bridges, D., Gould, M.K., Nerima, B., Mäser, P., Burchmore, R.J.S., and De Koning, H.P. (2007) Loss of the high affinity pentamidine transporter is responsible for high levels of crossresistance between arsenical and diamidine drugs in African trypanosomes. Mol. Pharmacol., 71, 1098-1108.
38. Carter, N.S. and Fairlamb, A.H. (1993) Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature, 361, 173-176.
39. Teka, I.A., Kazibwe, A., El-Sabbagh, N., Al Salabi, M.I.,Ward, C.P., Eze, A.A., Munday, J.C. et al. (2011) The diamidine diminazene aceturate is a substrate for the high affinity pentamidine transporter: implications for the development of high resistance levels. Mol. Pharmacol., 80, 110-116.
40. Lanteri, C.A., Tidwell, R.R., and Meshnick, S.R. (2008) The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei. Antimicrob. Agents Chemother., 52, 875-882.
41. Mathis, A.M., Holman, J.L., Sturk, L.M., Ismail, M.A., Boykin, D.W., Tidwell, R.R., and Hall, J.E. (2006) Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrob. Agents Chemother., 50, 2185-2191.
42. Coelho, A.C., Beverley, S.M., and Cotrim, P.C. (2003) Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol. Biochem. Parasitol., 130, 83-90.
43. Basselin, M., Denise, H., Coombs, G.H., and Barrett, M.P. (2002) Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob. Agents Chemother., 46, 3731-3738.
44. Mukherjee, A., Padmanabhan, P.K., Sahani, M.H., Barrett, M.P., and Madhubala, R. (2006) Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. Mol. Biochem. Parasitol., 145, 1-10.
45. Wilson, W.D., Tanious, F.A., Mathis, A., Tevis, D., Hall, J.E., and Boykin, D.W. (2008) Antiparasitic compounds that target DNA. Biochimie, 90, 999-1014.
46. Baraldi, P.G., Bovero, A., Fruttarolo, F., Preti, D., Tabrizi, M.A., Pavani, M.G., and Romagnoli, R. (2004) DNA minor groove binders as potential antitumor and antimicrobial agents. Med. Res. Rev., 24, 475-528.
47. Vincent, I.M., Creek, D.,Watson, D.G., Kamleh, M.A., Woods, D.J.,Wong, P.E., Burchmore, R.J., and Barrett, M.P. (2010) A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog., 6, e1001204.
48. Baker, N., Alsford, S., and Horn, D. (2011) Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol Biochem Parasitol., 176, 55-57.
49. Schumann Burkard, G., Jutzi, P., and Roditi, I. (2011) Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters. Mol. Biochem. Parasitol., 175, 91-94.
50. Burri, C. and Brun, R. (2003) Eflornithine for the treatment of human African trypanosomiasis. Parasitol. Res., 90, S49-S52.
51. Bitonti, A.J., Bacchi, C.J., McCann, P.P., and Sjoerdsma, A. (1986) Uptake of a-difluoromethylornithine by Trypanosoma brucei brucei. Biochem. Pharmacol., 35, 351-354.
52. Poulin, R., Lu, L., Ackermann, B., Bey, P., and Pegg, A.E. (1992) Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alphadifluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites. J. Biol. Chem., 267, 150-158.
53. Pérez-Victoria, F.J., Gamarro, F., Ouellette, M., and Castanys, S. (2003) Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem., 278, 49965-49971.
54. Pérez-Victoria, F.J., Sánchez-Cañete, M.P., Seifert, K., Croft, S.L., Sundar, S., Castanys, S., and Gamarro, F. (2006) Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist. Updat., 9, 26-39.
55. Pérez-Victoria, F.J., Sánchez-Cañete, M.P., Castanys, S., and Gamarro, F. (2006) Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J. Biol. Chem., 281, 23766-23775.
56. Borst, P. and Elferink, R.O. (2002) Mammalian ABC transporters in health and disease. Annu. Rev. Biochem., 71, 537-592.
57. Begley, D.J. (2004) ABC transporters and the blood-brain barrier. Curr. Pharm. Des., 10, 1295-1312.
58. Shahi, S.K., Krauth-Siegel, R.L., and Clayton, C.E. (2002) Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei. Mol. Microbiol., 43, 1129-1138.
59. Lüscher, A., Nerima, B., and Mäser, P. (2006) Combined contribution of TbAT1 and TbMRPA to drug resistance in Trypanosoma brucei. Mol. Biochem. Parasitol., 150, 364-366.
60. Alibu, V.P., Richter, C., Voncken, F., Marti, G., Shahi, S., Renggli, C.K., Seebeck, T. et al. (2006) The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. Mol. Biochem. Parasitol., 146, 38-44.
61. Wyllie, S., Cunningham, M.L., and Fairlamb, A.H. (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J. Biol. Chem., 279, 39925-39932.
62. Jones, P.M. and George, A.M. (2005) Multidrug resistance in parasites: ABC transporters, P-glycoproteins and molecular modelling. Int. J. Parasitol., 35, 555-566.
63. Légaré, D., Richard, D., Mukhopadhyay, R., Stierhof, Y.D., Rosen, B.P., Haimeur, A., Papadopoulou, B., and Ouellette, M. (2001) The Leishmania ATP-binding cassette protein PGPA is an intracellular metalthiol transporter ATPase. J. Biol. Chem., 276, 26301-26307.
64. Mukherjee, A., Padmanabhan, P.K., Singh, S., Roy, G., Girard, I., Chatterjee, M., Ouellette, M., and Madhubala, R. (2007) Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J. Antimicrob. Chemother., 59, 204-211.
65. Pérez-Victoria, J.M., Pérez-Victoria, F.J., Parodi-Talice, A., Jiménez, I.A., Ravelo, A. G., Castanys, S., and Gamarro, F. (2001) Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel Pglycoprotein-like transporter modulator. Antimicrob. Agents Chemother., 45, 2468-2474.
66. Pérez-Victoria, J.M., Cortés-Selva, F., Parodi-Talice, A., Bavchvarov, B.I., Pérez-Victoria, F.J., Muñoz-Martínez, F., Maitrejean, M. et al. (2006) Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux. Antimicrob. Agents Chemother., 50, 3102-3110.
67. Pérez-Victoria, J.M., Bavchvarov, B.I., Torrecillas, I.R., Martínez-García, M., López-Martín, C., Campillo, M. et al. (2011) Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania. Antimicrob. Agents Chemother., 55, 3838-3844.
68. Clausen, P.H., Leendertz, F.H., Blankenburg, A., Tietjen, U., Mehlitz, D., Sidibe, I.A., and Bauer, B. (1999) A drug incubation Glossina infectivity test (DIGIT) to assess the susceptibility of Trypanosoma congolense bloodstream forms to trypanocidal drugs (Xenodiagnosis). Acta. Trop., 72, 111-117.
69. Kaminsky, R., Gumm, I.D., Zweygarth, E., and Chuma, F. (1990) A drug incubation infectivity test (DIIT) for assessing resistance in trypanosomes. Vet. Parasitol., 34, 335-343.
70. Eisler, M.C., Gault, E.A., Moloo, S.K., Holmes, P.H., and Peregrine, A.S. (1997) Concentrations of isometamidium in the sera of cattle challenged with drug-resistant Trypanosoma congolense. Acta Trop., 63, 89-100.
71. Wilkes, J.M., Mulugeta,W., Wells, C.W., and Peregrine, A.S. (1997) Modulation of mitochondrial electrical potential: A candidate mechanism for drug resistance in African trypanosomes. Biochem. J., 326, 755-761.
72. Wang, P., Lee, C.S., Bayoumi, R., Djimde, A., Doumbo, O., Swedberg, G., Dao, L.D. et al. (1997) Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolte reductase alleles in a large number of field samples of diverse origins. Mol. Biochem. Parasitol., 89, 161-177.
73. Fidock, D.A., Nomura, T., Talley, A.K., Cooper, R.A., Dzekunov, S.M., Ferdig, M. T., Ursos, L.M. et al. (2000) Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRTand evidence for their role in chloroquine resistance. Mol. Cell, 6, 861-871.
74. Djimde, A., Doumbo, O.K., Cortese, J.F., Kayentao, K., Doumbo, S., Diourte, Y., Coulibaly, D. et al. (2001) A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med., 344, 257-263.
75. Barrett, M.P., Zhang, Z.Q., Denise, H., Giroud, C., and Baltz, T. (1995) A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity. Mol. Biochem. Parasitol., 73, 223-229.
76. Witola, W.H., Inoue, N., Ohashi, K., and Onuma, M. (2004) RNA-interference silencing of the adenosine transporter-1 gene in Trypanosoma evansi confers resistance to diminazene aceturate. Exp. Parasitol., 107, 47-57.
77. De Koning, H.P., Stewart, M., Anderson, L., Burchmore, R., Wallace, L.J.M., and Barrett, M.P. (2004) The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter; additional insights in diamidine resistance in African trypanosomes. Antimicrob. Agents Chemother., 48, 1515-1519.
78. Stewart, M.L., Burchmore, R.J., Clucas, C., Hertz-Fowler, C., Brooks, K., Tait, A., Macleod, A. et al. (2010) Multiple genetic mechanisms lead to loss of functional TbAT1 expression in drug-resistant trypanosomes. Eukaryot. Cell, 9, 336-343.
79. Delespaux, V., Chitanga, S., Geysen, D., Goethals, A., Van den Bossche, P., and Geerts, S. (2006) SSCP analysis of the P2 purine transporter TcoAT1 gene of Trypanosoma congolense leads to a simple PCR-RFLP test allowing the rapid identification of diminazene resistant stocks. Acta Trop., 100, 96-102.
80. Vitouley, H.S., Mungube, E.O., Allegye-Cudjoe, E., Diall, O., Bocoum, Z., Diarra, B., Randolph, T.F. et al. (2011) Improved PCR-RFLP for the detection of diminazene resistance in Trypanosoma congolense under field conditions using filter papers for sample storage. PLoS Negl. Trop. Dis., 5, e1223.
81. Avila, H., Goncalves, A.M., Nehme, N.S., Morel, C.M., and Simpson, L. (1990) Schizodeme analysis of Trypanosoma cruzi stocks from South and Central America by analysis of PCR-amplified minicircle variable region sequences. Mol. Biochem. Parasitol., 42, 175-187.
82. De Koning, H.P. (2008) Ever-increasing complexities of diamidine and arsenical cross-resistance in African trypanosomes. Trends Parasitol., 24, 345-349.
83. Chitanga, S., Marcotty, T., Namangala, B., Van den Bossche, P., Van den Abbeele, J., and Delespaux, V. (2011) High prevalence of drug resistance in animal trypanosomes without a history of drug exposure. PLoS Negl. Trop. Dis., 5, e1454.
84. Geysen, D., Delespaux, V., and Geerts, S. (2003) PCR-RFLP using Ssu-rDNA amplification as an easy method for species-specific diagnosis of Trypanosoma species in cattle. Vet. Parasitol., 110, 171-180.
85. Delespaux, V., Dinka, H., Masumu, J., Van den Bossche, P., and Geerts, S. (2008) Fivefold increase in the proportion of diminazene aceturate resistant Trypanosoma congolense isolates over a seven years period in Eastern Zambia. Drug Resist. Updat., 11, 205-209.
86. Moti, G.Y., Fikru, R., Van den Abbeele, J., Büscher, P., Van den Bossche, P., Duchateau, L. et al. (2012) Ghibe river basin in Ethiopia: present situation of trypanocidal drug resistance in Trypanosoma congolense using tests in mice and PCR-RFLP. Vet. Parasitol., 189, 197-203.
87. Mamoudou, A., Delespaux, V., Chepnda, V., Hachimou, Z., Andrikaye, J.P., Zoli, A., and Geerts, S. (2008) Assessment of the occurrence of trypanocidal drug resistance in trypanosomes of naturally infected cattle in the Adamaoua region of Cameroon using the standard mouse test and molecular tools. Acta Trop., 106, 115-118.